<DOC>
	<DOCNO>NCT00959361</DOCNO>
	<brief_summary>INTRODUCTION : Studies prove pharmaceutical care ( PC ) increase adherence antiretroviral ; thus , increase undetectable viral load . The viral load diminishes , prevalence undetectable viral load increase , level adherence treatment increase , general necessary high adhesion reach effectiveness therapeutic . Increasing adherence level , increase survive chance quality life diminishes transmission risk . Studies demonstrate self-effectiveness expectation use medication correctly main predictor adherence , complex therapeutic regimen , perception side effect , small adherence , highlight importance preventing , identify solve problem treatment antiretroviral , problem related medication ( PRM ) PC . OBJECTIVES : To evaluate effectiveness PC adherence HIV-patients antiretroviral therapy , identify , prevent solve PRMs treatment . METHODOLOGY : One-side randomized clinical trail control non-intervention parallel . 332 patient randomize include control intervention group ( PC ) . Questionnaires apply : sociodemographic , adherence antiretroviral self-report , smoke , BECK ( depression ) , CAGE ( problem relate alcohol consumption ) self-effectiveness , expectation result social support . Each 4 month measure viral load CD4 carry . The one PC group receive card information medication medicine identify different color . The follow-up last one year accord instruction DADER program .</brief_summary>
	<brief_title>Evaluation Effectiveness Pharmaceutical Care Adherence HIV-Positive Patients Antiretroviral Therapy</brief_title>
	<detailed_description>Election sample : 332 select consecutively patient register SAE-Pelotas GENERAL OBJECTIVE To evaluate effectiveness Pharmaceutical Care adherence antiretroviral therapy HIV- positive patient . PRIMARY OBJECTIVE The relative risk adherence antiretroviral treatment among HIV-positive patient receive Pharmaceutical Care one receive Pharmaceutical Care different 1 . SECONDARY OBJECTIVE The relative risk undetectable viral load among HIV-positive patient receive Pharmaceutical Care one receive Pharmaceutical Care different 1 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>HIV Seropositivity</mesh_term>
	<criteria>patient register SAEPelotas adult ( old 18 year ) inhabitant urban zone Pelotas pregnant use antiretroviral treatment independent time treatment accept participate research signature write informed consent The enclosed patient randomize program computerize group pharmaceutical care control group . non signature write informed consent incapacity answer instrument data collection inhabitant urban zone Pelotas patient could follow 12 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>patient compliance</keyword>
	<keyword>guideline adherence</keyword>
	<keyword>advance directive adherence</keyword>
	<keyword>treatment refusal</keyword>
	<keyword>directly observe therapy</keyword>
	<keyword>anti-retroviral agent</keyword>
	<keyword>HIV seropositivity</keyword>
	<keyword>HIV infection</keyword>
	<keyword>HIV</keyword>
	<keyword>pharmaceutical service</keyword>
	<keyword>HIV-positives patient</keyword>
	<keyword>treatment experience</keyword>
</DOC>